Intersection of Sleep and Psychiatric Disorders


A sleep specialist highlights what to watch out for in your patients.

Dr Richard Bogan discusses the ins and outs of sleep and psychiatric disorders and shares his thoughts about a recent FDA approval of XYWAV (calcium, magnesium, potassium, and sodium oxybates), indicated for the treatment of narcolepsy. XYWAV, manufactured by Jazz Pharmaceuticals, is "the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years."

Dr Bogan is Medical Director, SleepMed of South Carolina; Chief Medical Officer, SleepMed, Inc; Associate Clinical Professor, University of South Carolina School of Medicine; and Associate Clinical Professor, Medical University of South Carolina in Charleston, SC.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.